Pub Date : 2021-02-15DOI: 10.1158/1538-7445.SABCS20-PD2-09
M. Goetz, G. Fleming, M. Kuffel, J. Hawse, J. Black, R. Weinshilboum, J. Ingle, P. Dell'Orto, O. Biasi, R. Kammler, S. Loi, M. Colleoni, G. Viale, P. Francis, M. Regan
Tamoxifen (T) is a pro-drug that undergoes CYP2D6-mediated metabolic activation to metabolites that more potently inhibit estrogen stimulated growth compared to the parent drug. While many studies have examined the role of CYP2D6 genotype in T-treated postmenopausal women, the role of CYP2D6 metabolism in premenopausal women (pre-MW) receiving T, with or without ovarian function suppression (OFS) or exemestane (E) and OFS is unknown. Methods: SOFT randomized 3066 (pre-MW) from 2003-2011 in 27 countries, stratified according to prior receipt or nonreceipt of chemotherapy and nodal status, to receive 5 years of T, T+OFS, or E+OFS. We designed a pharmacogenetics substudy (activated October 2010) to collect blood DNA from North American (NA) patients (pts) or to extract non-tumor DNA from available formalin fixed paraffin embedded (FFPE) tissue blocks. For pts with a blood sample, CYP2D6 was genotyped beginning with the Luminex Tag-It Mutation Detection Kit and when needed, with a copy number variation assay and/or sequencing assays. For pts with FFPE-derived DNA, CYP2D6 genotyping for *3, *4, *6, *9, *10, *17 and *41 was performed using a Taqman Allelic Discrimination Assay. CYP2D6 phenotypes were called by classifying pts on the basis of a combination of poor (PM: *3, *4, *5, *6, *7, *8), slow (SM: *10), intermediate (IM: *9, *17, *29, *41) and extensive metabolizer alleles (EM; all others). Activity scores (AS) from phenotypes assigned for each allele: 0 if PM, 0.25 if SM, 0.5 if IM and 1 if EM allele, and multiplied x2 or x3 if duplicate or triplicate. With concomitant use of potent CYP2D6 inhibitor, AS=0; use of weak inhibitor subtracted 0.5. Metabolizer status was defined by CYP2D6 genotype alone or in combination with CYP2D6 inhibitor use at randomization from the AS: extensive (AS 1.25 to 3), intermediate (AS >0.5 to 0.3 ng/ml in 1053, and successfully derived CYP2D6 genotypes for 765/3047 pts (25%). 182 (15%) pts had DFS events after 8 yrs median follow-up. Metabolizer status from genotype was 57% extensive, 29% intermediate, 15% slow/poor. Metabolizer status was not associated with DFS in pts assigned T alone (P=0.60; Table), nor in pts assigned T+OFS (P=0.41) or E+OFS (P=0.30). 11% of pts used CYP2D6 inhibitors concomitantly at randomization; for 8% it changed the metabolizer status. The results using this definition were consistent. Conclusion: This retrospective-prospective SOFT pharmacogenetics substudy found no relation of CYP2D6 metabolizer status with DFS in premenopausal pts receiving T, T + OFS, or E + OFS. Given that 50% were pretreated with chemotherapy, further study is needed regarding the role of CYP2D6 metabolism in patients treated with T monotherapy. Citation Format: Matthew P. Goetz, Gini F. Fleming, Mary Kuffel, John R. Hawse, John L. Black, Richard Weinshilboum, James N. Ingle, Patrizia dell’Orto, Olivia Biasi, Roswitha Kammler, Sherene Loi, Marco Colleoni, Giuseppe Viale, Prudence A Francis, Meredith M Regan. The role o
他莫昔芬(T)是一种前药，经过cyp2d6介导的代谢激活产生代谢物，与母体药物相比，更有效地抑制雌激素刺激的生长。虽然许多研究已经检查了CYP2D6基因型在接受T治疗的绝经后妇女中的作用，但CYP2D6代谢在接受T治疗的绝经前妇女(pre-MW)中，有或没有卵巢功能抑制(OFS)或依西美坦(E)和OFS的作用尚不清楚。方法:SOFT随机抽取来自27个国家2003-2011年的3066例(pre-MW)患者，根据既往接受或未接受化疗和淋巴结状态进行分层，接受5年的T、T+OFS或E+OFS治疗。我们设计了一项药物遗传学亚研究(2010年10月启动)，从北美(NA)患者(pts)收集血液DNA，或从可用的福尔马林固定石蜡包埋(FFPE)组织块中提取非肿瘤DNA。对于有血液样本的患者，从Luminex Tag-It突变检测试剂盒开始进行CYP2D6基因分型，必要时进行拷贝数变异试验和/或测序试验。对于来自ffpe DNA的患者，采用Taqman等位基因区分法对*3、*4、*6、*9、*10、*17和*41进行CYP2D6基因分型。CYP2D6表型是根据不良(PM: *3、*4、*5、*6、*7、*8)、缓慢(SM: *10)、中间(IM: *9、*17、*29、*41)和广泛代谢等位基因(EM;所有人)。每个等位基因的表型活性评分(AS)为:PM为0,SM为0.25,IM为0.5,EM为1，重复或三次则乘以x2或x3。同时使用强效CYP2D6抑制剂，AS=0;使用弱抑制剂减去0.5。代谢状态由CYP2D6基因型单独或与CYP2D6抑制剂联合使用来定义，随机从AS:广泛(AS 1.25至3)，中间(AS >0.5至0.3 ng/ml，在1053中，765/3047例(25%)成功衍生CYP2D6基因型。182(15%)名患者在中位随访8年后出现DFS事件。基因型代谢状态57%为广泛，29%为中等，15%为慢/差。在单独分配T治疗的患者中，代谢状态与DFS无关(P=0.60;T+OFS组(P=0.41)或E+OFS组(P=0.30)亦无差异。随机分组时，11%的患者同时使用CYP2D6抑制剂;对8%的人来说，它改变了代谢状态。使用这一定义的结果是一致的。结论:这项回顾性-前瞻性SOFT药物遗传学亚研究发现，在接受T、T + OFS或E + OFS治疗的绝经前患者中，CYP2D6代谢状态与DFS无关。考虑到50%的患者进行了化疗预处理，CYP2D6代谢在T单药治疗患者中的作用有待进一步研究。引文格式:Matthew P. Goetz, Gini F. Fleming, Mary Kuffel, John R. Hawse, John L. Black, Richard Weinshilboum, James N. Ingle, Patrizia dell 'Orto, Olivia Biasi, Roswitha Kammler, Sherene Loi, Marco Colleoni, Giuseppe Viale, Prudence A Francis, Meredith M Regan。CYP2D6介导的他莫昔芬代谢在抑制卵巢功能试验(SOFT)中的作用[摘要]。参见:2020年圣安东尼奥乳腺癌虚拟研讨会论文集;2020年12月8-11日;费城(PA): AACR;癌症杂志，2021;81(4增刊):摘要nr PD2-09。
{"title":"Abstract PD2-09: The role of CYP2D6 mediated tamoxifen metabolism in the suppression of ovarian function trial (SOFT)","authors":"M. Goetz, G. Fleming, M. Kuffel, J. Hawse, J. Black, R. Weinshilboum, J. Ingle, P. Dell'Orto, O. Biasi, R. Kammler, S. Loi, M. Colleoni, G. Viale, P. Francis, M. Regan","doi":"10.1158/1538-7445.SABCS20-PD2-09","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS20-PD2-09","url":null,"abstract":"Tamoxifen (T) is a pro-drug that undergoes CYP2D6-mediated metabolic activation to metabolites that more potently inhibit estrogen stimulated growth compared to the parent drug. While many studies have examined the role of CYP2D6 genotype in T-treated postmenopausal women, the role of CYP2D6 metabolism in premenopausal women (pre-MW) receiving T, with or without ovarian function suppression (OFS) or exemestane (E) and OFS is unknown. Methods: SOFT randomized 3066 (pre-MW) from 2003-2011 in 27 countries, stratified according to prior receipt or nonreceipt of chemotherapy and nodal status, to receive 5 years of T, T+OFS, or E+OFS. We designed a pharmacogenetics substudy (activated October 2010) to collect blood DNA from North American (NA) patients (pts) or to extract non-tumor DNA from available formalin fixed paraffin embedded (FFPE) tissue blocks. For pts with a blood sample, CYP2D6 was genotyped beginning with the Luminex Tag-It Mutation Detection Kit and when needed, with a copy number variation assay and/or sequencing assays. For pts with FFPE-derived DNA, CYP2D6 genotyping for *3, *4, *6, *9, *10, *17 and *41 was performed using a Taqman Allelic Discrimination Assay. CYP2D6 phenotypes were called by classifying pts on the basis of a combination of poor (PM: *3, *4, *5, *6, *7, *8), slow (SM: *10), intermediate (IM: *9, *17, *29, *41) and extensive metabolizer alleles (EM; all others). Activity scores (AS) from phenotypes assigned for each allele: 0 if PM, 0.25 if SM, 0.5 if IM and 1 if EM allele, and multiplied x2 or x3 if duplicate or triplicate. With concomitant use of potent CYP2D6 inhibitor, AS=0; use of weak inhibitor subtracted 0.5. Metabolizer status was defined by CYP2D6 genotype alone or in combination with CYP2D6 inhibitor use at randomization from the AS: extensive (AS 1.25 to 3), intermediate (AS >0.5 to 0.3 ng/ml in 1053, and successfully derived CYP2D6 genotypes for 765/3047 pts (25%). 182 (15%) pts had DFS events after 8 yrs median follow-up. Metabolizer status from genotype was 57% extensive, 29% intermediate, 15% slow/poor. Metabolizer status was not associated with DFS in pts assigned T alone (P=0.60; Table), nor in pts assigned T+OFS (P=0.41) or E+OFS (P=0.30). 11% of pts used CYP2D6 inhibitors concomitantly at randomization; for 8% it changed the metabolizer status. The results using this definition were consistent. Conclusion: This retrospective-prospective SOFT pharmacogenetics substudy found no relation of CYP2D6 metabolizer status with DFS in premenopausal pts receiving T, T + OFS, or E + OFS. Given that 50% were pretreated with chemotherapy, further study is needed regarding the role of CYP2D6 metabolism in patients treated with T monotherapy. Citation Format: Matthew P. Goetz, Gini F. Fleming, Mary Kuffel, John R. Hawse, John L. Black, Richard Weinshilboum, James N. Ingle, Patrizia dell’Orto, Olivia Biasi, Roswitha Kammler, Sherene Loi, Marco Colleoni, Giuseppe Viale, Prudence A Francis, Meredith M Regan. The role o","PeriodicalId":415047,"journal":{"name":"Poster Spotlight Session Abstracts","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123840040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.sabcs20-pd4-01
C. Tinterri, E. Marrazzo, C. Anghelone, E. Barbieri, A. Sagona, A. Bottini, A. Rubino, D. Gentile, W. Gatzemeier, V. Errico, A. Testori, G. Canavese
{"title":"Abstract PD4-01: Preservation of axillary lymph nodes compared to complete dissection in T1-T2 breast cancer patients presenting 1-2 metastatic sentinel lymph nodes : A multicenter randomized clinical trial. Sinodar One.","authors":"C. Tinterri, E. Marrazzo, C. Anghelone, E. Barbieri, A. Sagona, A. Bottini, A. Rubino, D. Gentile, W. Gatzemeier, V. Errico, A. Testori, G. Canavese","doi":"10.1158/1538-7445.sabcs20-pd4-01","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs20-pd4-01","url":null,"abstract":"","PeriodicalId":415047,"journal":{"name":"Poster Spotlight Session Abstracts","volume":"131 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121475198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.SABCS20-PD7-05
J. Carter, J. Boughey, Jun He, V. Suman, Xue Wang, J. Kachergus, Krishna R. Kalari, Liewei Wang, R. Weinshilboum, A. Moyer, S. Mclaughlin, A. Moreno-Aspitia, D. Northfelt, R. Gray, J. Ingle, E. Thompson, M. Goetz
{"title":"Abstract PD7-05: Neoadjuvant chemotherapy selectively alters spatially-defined immune landscapes in clinical luminal B HR+/HER2- breast cancers: Analysis of the breast cancer genome guided therapy study (BEAUTY)","authors":"J. Carter, J. Boughey, Jun He, V. Suman, Xue Wang, J. Kachergus, Krishna R. Kalari, Liewei Wang, R. Weinshilboum, A. Moyer, S. Mclaughlin, A. Moreno-Aspitia, D. Northfelt, R. Gray, J. Ingle, E. Thompson, M. Goetz","doi":"10.1158/1538-7445.SABCS20-PD7-05","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS20-PD7-05","url":null,"abstract":"","PeriodicalId":415047,"journal":{"name":"Poster Spotlight Session Abstracts","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116316510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.SABCS20-PD8-03
Xiaoyong Fu, Resel Pereira, L. Qin, C. Angelis, Sarmistha Nanda, M. Shea, A. Nardone, R. Jeselsohn, Ofir Cohen, N. Wagle, M. Rimawi, C. Osborne, R. Schiff
{"title":"Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer","authors":"Xiaoyong Fu, Resel Pereira, L. Qin, C. Angelis, Sarmistha Nanda, M. Shea, A. Nardone, R. Jeselsohn, Ofir Cohen, N. Wagle, M. Rimawi, C. Osborne, R. Schiff","doi":"10.1158/1538-7445.SABCS20-PD8-03","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS20-PD8-03","url":null,"abstract":"","PeriodicalId":415047,"journal":{"name":"Poster Spotlight Session Abstracts","volume":"144 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127488333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.sabcs20-pd11-09
A. O'Shea, G. Clifton, N. Qiao, B. Heckman-Stoddard, M. Wojtowicz, E. Dimond, I. Bedrosian, D. Weber, Alexander Husband, R. Pastorello, L. Vornik, G. Peoples, E. Mittendorf
{"title":"Abstract PD11-09: Vadis trial: Phase II trial of nelipepimut-s peptide vaccine in women with DCIS of the breast","authors":"A. O'Shea, G. Clifton, N. Qiao, B. Heckman-Stoddard, M. Wojtowicz, E. Dimond, I. Bedrosian, D. Weber, Alexander Husband, R. Pastorello, L. Vornik, G. Peoples, E. Mittendorf","doi":"10.1158/1538-7445.sabcs20-pd11-09","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs20-pd11-09","url":null,"abstract":"","PeriodicalId":415047,"journal":{"name":"Poster Spotlight Session Abstracts","volume":"467 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115285649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-15DOI: 10.1158/1538-7445.SABCS20-PD12-12
M. Murugappan, B. King-Kallimanis, Christina Mangir, Lyn Howie, V. Bhatnagar, J. Beaver, E. Basch, P. Kluetz
{"title":"Abstract PD12-12: Floor and ceiling effects in the EORTC QLQ-C30 physical functioning subscale among patients with breast cancer enrolled in commercial clinical trials vs. a community trial","authors":"M. Murugappan, B. King-Kallimanis, Christina Mangir, Lyn Howie, V. Bhatnagar, J. Beaver, E. Basch, P. Kluetz","doi":"10.1158/1538-7445.SABCS20-PD12-12","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS20-PD12-12","url":null,"abstract":"","PeriodicalId":415047,"journal":{"name":"Poster Spotlight Session Abstracts","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132317405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-15DOI: 10.1158/1538-7445.sabcs19-pd3-09
P. Thompson, Chuan Huang, B. Wertheim, C. Preece, Jie Yang, Jessica A. Martinez, D. Roe, P. Chalasani, A. Stopeck
Background. Preclinical and observational evidence supports cancer prevention activity of non-steroidal anti-inflammatory drugs (NSAIDs) in the breast via suppression of prostaglandin E2 (PGE2) synthesis by cyclooxygenase-2 (COX2). Evidence includes linking of PGE2 to aromatase activity and estrogen synthesis in breast adipose tissue, as well as effects on collagen and breast density (BD). Methods. In an open-label trial, we evaluated the effect of the non-selective NSAID sulindac at 150 mg bid for 12 months on BD in 52 postmenopausal women taking adjuvant aromatase inhibitors (AIs) for breast cancer. BD was measured using a fat-water decomposition MRI based BD measure (MRD) previously shown to be more quantitative than mammographic density. A non-randomized observation cohort of 46 postmenopausal women on AI without NSAID use was conducted in parallel to assess the effect of AI on MRD over 12 months. Eligible participants were recruited at two study sites and included women with an intact, unaffected contralateral breast and BI-RADS ≥ 2. Each subject’s MRI_BD measures at baseline and at 6 and 12 months were included in linear mixed models for longitudinal data. Log-transformation was applied to the outcome of BD. Covariates included log-transformed baseline BD, time on AI, and baseline body mass index (BMI) and change in BMI. Breast tissue collagen fiber alignment for 30 women with paired breast biopsies, before and after 6 months on sulindac, was examined using Second-Harmonic Generation (SHG) microscopy and analysis of the distribution (histogram) of ‘straight’ fibers in three randomly selected areas of breast tissue. Straightness of individual fibers was calculated as the linear length of a fiber divided by the distance along the fiber. Results. Participants on sulindac intervention had a significant change in BD relative to baseline BD at 6 (p=0.05) and 12 months (p Citation Format: Patricia Thompson, Chuan Huang, Betsy Wertheim, Christina Preece, Jie Yang, Jessica Martinez, Denise Roe, Pavani Chalasani, Alison Stopeck. Sulindac reduces breast density and alters collagen alignment in patients on aromatase inhibitors [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD3-09.
{"title":"Abstract PD3-09: Sulindac reduces breast density and alters collagen alignment in patients on aromatase inhibitors","authors":"P. Thompson, Chuan Huang, B. Wertheim, C. Preece, Jie Yang, Jessica A. Martinez, D. Roe, P. Chalasani, A. Stopeck","doi":"10.1158/1538-7445.sabcs19-pd3-09","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs19-pd3-09","url":null,"abstract":"Background. Preclinical and observational evidence supports cancer prevention activity of non-steroidal anti-inflammatory drugs (NSAIDs) in the breast via suppression of prostaglandin E2 (PGE2) synthesis by cyclooxygenase-2 (COX2). Evidence includes linking of PGE2 to aromatase activity and estrogen synthesis in breast adipose tissue, as well as effects on collagen and breast density (BD). Methods. In an open-label trial, we evaluated the effect of the non-selective NSAID sulindac at 150 mg bid for 12 months on BD in 52 postmenopausal women taking adjuvant aromatase inhibitors (AIs) for breast cancer. BD was measured using a fat-water decomposition MRI based BD measure (MRD) previously shown to be more quantitative than mammographic density. A non-randomized observation cohort of 46 postmenopausal women on AI without NSAID use was conducted in parallel to assess the effect of AI on MRD over 12 months. Eligible participants were recruited at two study sites and included women with an intact, unaffected contralateral breast and BI-RADS ≥ 2. Each subject’s MRI_BD measures at baseline and at 6 and 12 months were included in linear mixed models for longitudinal data. Log-transformation was applied to the outcome of BD. Covariates included log-transformed baseline BD, time on AI, and baseline body mass index (BMI) and change in BMI. Breast tissue collagen fiber alignment for 30 women with paired breast biopsies, before and after 6 months on sulindac, was examined using Second-Harmonic Generation (SHG) microscopy and analysis of the distribution (histogram) of ‘straight’ fibers in three randomly selected areas of breast tissue. Straightness of individual fibers was calculated as the linear length of a fiber divided by the distance along the fiber. Results. Participants on sulindac intervention had a significant change in BD relative to baseline BD at 6 (p=0.05) and 12 months (p Citation Format: Patricia Thompson, Chuan Huang, Betsy Wertheim, Christina Preece, Jie Yang, Jessica Martinez, Denise Roe, Pavani Chalasani, Alison Stopeck. Sulindac reduces breast density and alters collagen alignment in patients on aromatase inhibitors [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD3-09.","PeriodicalId":415047,"journal":{"name":"Poster Spotlight Session Abstracts","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130443600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-14DOI: 10.1158/1538-7445.sabcs19-pd7-05
K. Jhaveri, E. Winer, E. Lim, Jose AlejandroPerez Fidalgo, M. Bellet, I. Mayer, V. Boni, J. Patel, A. Bardia, Jose M Garcia, P. Kabos, Mary Gates, Ya-Chi Chen, J. Fredrickson, Xiaojing Wang, L. Friedman, J. Spoerke, S. Gendreau, Ciara Metcalfe, Lichuan Liu, Ching-Wei Chang, S. Monemi, Monica Gonzalez, U. McCurry, S. Milan, E. Humke, S. Loi
{"title":"Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer","authors":"K. Jhaveri, E. Winer, E. Lim, Jose AlejandroPerez Fidalgo, M. Bellet, I. Mayer, V. Boni, J. Patel, A. Bardia, Jose M Garcia, P. Kabos, Mary Gates, Ya-Chi Chen, J. Fredrickson, Xiaojing Wang, L. Friedman, J. Spoerke, S. Gendreau, Ciara Metcalfe, Lichuan Liu, Ching-Wei Chang, S. Monemi, Monica Gonzalez, U. McCurry, S. Milan, E. Humke, S. Loi","doi":"10.1158/1538-7445.sabcs19-pd7-05","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs19-pd7-05","url":null,"abstract":"","PeriodicalId":415047,"journal":{"name":"Poster Spotlight Session Abstracts","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124979599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：